» Articles » PMID: 20336156

Near-perfect Infectivity of Wild-type AAV As Benchmark for Infectivity of Recombinant AAV Vectors

Overview
Journal Gene Ther
Date 2010 Mar 26
PMID 20336156
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Viral vectors derived from adeno-associated viruses (AAVs) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently shown immunological complications in clinical trials, highlight the necessity to define the specific activity of vector preparations beyond current standards. In this report, we determined the infectious, physical and genome-containing particle titers of several wild-type AAV type 2 (wtAAV2) and recombinant AAV type 2 (rAAV2) preparations that were produced and purified by standard methods. We found that the infectivity of wtAAV2 approaches a physical-to-infectious particle ratio of one. This near-perfect physical-to-infectious particle ratio defines a 'ceiling' for the theoretically achievable quality of recombinant AAV vectors. In comparison, for rAAV2, only approximately 50 out of 100 viral particles contained a genome and, more strikingly, only approximately 1 of the 100 viral particles was infectious. Our findings suggest that current strategies for rAAV vector design, production and/or purification should be amenable to improvements. Ultimately, this could result in the generation of near-perfect vector particles, a prospect with significant implications for gene therapy.

Citing Articles

Development of cell lines with increased susceptibility to diverse adeno-associated viral vectors to enable potency assays.

Zengel J, Esterman E, Ponnuswami A, Wall N, Carette J Mol Ther Methods Clin Dev. 2025; 33(1):101416.

PMID: 40008089 PMC: 11851225. DOI: 10.1016/j.omtm.2025.101416.


Improved Recombinant Adeno-Associated Viral Vector Production via Molecular Evolution of the Viral Rep Protein.

Steininger T, Ottl V, Franken L, Frank C, Ohland P, Lopez Ferreiro M Int J Mol Sci. 2025; 26(3).

PMID: 39941089 PMC: 11818820. DOI: 10.3390/ijms26031319.


Comparative transcriptomic and proteomic kinetic analysis of adeno-associated virus production systems.

Lin Y, Lu M, Cai W, Hu W Appl Microbiol Biotechnol. 2024; 108(1):385.

PMID: 38896252 PMC: 11186941. DOI: 10.1007/s00253-024-13203-5.


Quality control for Adeno-associated viral vector production.

Ersing I, Rego M, Wang C, Zhang Y, DeMaio K, Tillgren M Neuromethods. 2024; 195:77-101.

PMID: 38585382 PMC: 10997381. DOI: 10.1007/978-1-0716-2918-5_5.


Unveiling the secrets of adeno-associated virus: novel high-throughput approaches for the quantification of multiple serotypes.

Meierrieks F, Kour A, Patz M, Pflanz K, Wolff M, Pickl A Mol Ther Methods Clin Dev. 2023; 31:101118.

PMID: 37822717 PMC: 10562196. DOI: 10.1016/j.omtm.2023.101118.


References
1.
Mingozzi F, Maus M, Hui D, Sabatino D, Murphy S, Rasko J . CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007; 13(4):419-22. DOI: 10.1038/nm1549. View

2.
Debelak D, Fisher J, Iuliano S, Sesholtz D, Sloane D, Atkinson E . Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2. J Chromatogr B Biomed Sci Appl. 2000; 740(2):195-202. DOI: 10.1016/s0378-4347(00)00100-6. View

3.
Zen Z, Espinoza Y, Bleu T, Sommer J, Wright J . Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum Gene Ther. 2004; 15(7):709-15. DOI: 10.1089/1043034041361262. View

4.
Clark K, Voulgaropoulou F, Fraley D, Johnson P . Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther. 1995; 6(10):1329-41. DOI: 10.1089/hum.1995.6.10-1329. View

5.
Ferrari F, Samulski T, Shenk T, Samulski R . Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996; 70(5):3227-34. PMC: 190186. DOI: 10.1128/JVI.70.5.3227-3234.1996. View